(Q36224475)

English

Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Munehiro Yoshitomi

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Shigeru Yutani

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Satoko Matsueda

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Tetsuya Ioji

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Nobukazu Komatsu

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Shigeki Shichijo

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Akira Yamada

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kyogo Itoh

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Tetsuro Sasada

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Hisafumi Kinoshita

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

20 December 2011

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Experimental and Therapeutic Medicine

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

463-469

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Improved Endpoints for Cancer Immunotherapy Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Genetics of biliary tract cancers and emerging targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

T(H)17 cells in tumour immunity and immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Personalized peptide vaccines: a new therapeutic modality for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

1 October 2017

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

22 September 2018

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

22 September 2018

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

22 September 2018

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

22 September 2018

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

22 September 2018

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

22 September 2018

Elevated serum interleukin-6 levels in patients with pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3438646

22 September 2018

New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization

1 reference

https://pubmed.ncbi.nlm.nih.gov/22969912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

1 reference

https://pubmed.ncbi.nlm.nih.gov/22969912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum interleukin 6 as a prognostic factor in patients with prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22969912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22969912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker

1 reference

https://pubmed.ncbi.nlm.nih.gov/22969912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3892/ETM.2011.424

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36224475&oldid=1982089703"